Jaguar Health, Altamira Therapeutics,Erasca Among Healthcare Movers
Protagenic Therapeutics pressure-regulating peptides showed excellent safety in the single-dose portion of the Phase I trial
Protagenic Therapeutics pressure-regulating peptides showed excellent safety in the single-dose portion of the Phase I trial
Express News | Protagenic Therapeutics Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial
Protagenic Therapeutics' Reports Safety Data From Single Dose Portion Of Phase 1 Trial Involving PT00114
No Clinically-Relevant Adverse Events Reported in Single Dose Portion, Multiple Dose Portion to Commence
Protagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric Disorders
10-Q: Quarterly report
10-K/A: Annual report (Amendment)
Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial
NEW YORK, NY / ACCESSWIRE / May 1, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today announced the completion of enrollment in the single dose portion
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersTevogen Bio Holdings (NASDAQ:TVGN) shares rose 75.3% to $1.49 during Friday's pre-market session. The company's market cap stands at $245.2 million. Cryo-Cell International (AMEX:CCEL) shares i
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersAclarion (NASDAQ:ACON) shares moved upwards by 66.7% to $0.48 during Thursday's regular session. The market value of their outstanding shares is at $3.4 million. Processa Pharma (NASDAQ:PCSA) s
KOPN, BTCM and CETX Among Mid-day Movers
Protagenic Therapeutics' Peptide PT00114 To Be Highlighted At Boston Summit In Presentation Titled "Novel Blood-Brain Barrier Penetrating Peptide: Opening New Doors in Neuro-Psychiatric Treatment" On April 23, 2024
Topic: Novel Blood-Brain Barrier Penetrating Peptide: Opening New Doors in Neuro-Psychiatric Treatment
Earnings Call Summary | Protagenic Therapeutics(PTIX.US) Q4 2023 Earnings Conference
The following is a summary of the Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call Transcript:Financial Performance:Protagenic Therapeutics reported an increase in Research and Development (
Protagenic Therapeutics FY23 EPS $(1.15) Down From $(0.82) YoY
Protagenic Therapeutics FY23 EPS $(1.15) Down From $(0.82) YoY
Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results
Transitioned from Pre-Clinical to Clinical Stage company in FY 2023Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Gene
Earnings Scheduled For April 1, 2024
Companies Reporting Before The Bell • Mach Natural Resources (NYSE:MNR) is projected to report quarterly earnings at $0.92 per share on revenue of $213.43 million. • Sharps Technology (NASDAQ:STSS) is
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders
Next clinical progress update expected in April 2024NEW YORK, NY / ACCESSWIRE / March 27, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, advances its mis
Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice
NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Protagenic Therapeutics, Inc. , a biopharmaceutical innovator, regained compliance with Nasdaq Listing Rule 5550 as the closing bid price of shares of PTIX
EYEN, BYSI and FENG Among Mid-day Movers
Protagenic Advances in Stress Disorder Treatment Trial
No Data